Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Long term safety and long term disease control of oral ixazomib and short-course rituximab in untreated iNHL

View Full Paper
Ask AI
Bookmark
Share

Authors

SGSolomon A. GrafCUChaitra UjjaniTGTed Gooley

Discussion

Loading...

Member takes

Overview

Observational analysis shows improved progression free survival and safety with ixazomib and rituximab therapy in untreated iNHL, highlighting long-term efficacy.

Key Points

  • Long term use of ixazomib with rituximab achieved a median progression free survival of 79 months in treated patients.
  • Fifty-three percent of long term patients had high tumor burden, yet grade 3 adverse events remained minimal over time.
  • Assessment of adverse events revealed only 2 related to ixazomib after 12 months, with other serious conditions considered unrelated to the therapy.
  • Findings indicate the potential of ixazomib for durable disease control in iNHL, especially in regions with fewer resources.

Cite This Study

Graf et al. (2025) studied this question.

synapsesocial.com/papers/69362f5a4fa91c937236db56https://doi.org/10.1182/blood-2025-5355
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1An open-label rollover study to assess the long-term safety of ixazomib2025
  2. 2Real-world efficacy and safety of ixazomib maintenance therapy in Chinese patients with newly diagnosed multiple myeloma: A multicenter retrospective study2025
  3. 3Treatment outcomes in patients with newly diagnosed multiple myeloma receiving ixazomib as initial therapy: A retrospective, observational, real-world historical database analysis from China2025
  4. 4Single-agent rituximab and ultra-low-dose adaptive radiotherapy for the treatment of indolent B-cell non-Hodgkin lymphomas2025 · 1 citations
  5. 5Long-term outcomes of a novel initial regimen: Rituximab plus pegylated interferon α-2b in untreated advanced indolent B-cell lymphoma – 5-year follow-up of the ripple study2025